|Min SIP Amount||₹500|
|NAV||₹121.15 (20 Sep 2019)|
|Fund Started||01 Jan 2013|
|Fund Size||₹902 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||12.5%|
|Divi's Laboratories Ltd.||Healthcare||Equity||9.7%|
|Alkem Laboratories Ltd.||Healthcare||Equity||6.0%|
|Strides Pharma Science Ltd.||Healthcare||Equity||5.4%|
|Torrent Pharmaceuticals Ltd.||Healthcare||Equity||5.1%|
|Ajanta Pharma Ltd.||Healthcare||Equity||4.5%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||4.3%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||4.3%|
SBI Healthcare Opportunities Fund Direct Plan Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was introduced to investors on 01 Jan 2013. Tanmaya Desai is the Current Fund Manager of SBI Healthcare Opportunities Fund Direct Plan Growth.The fund currently has an Asset Under Management(AUM) of ₹902 Cr and the Latest NAV as of 20 Sep 2019 is ₹121.15.
The SBI Healthcare Opportunities Fund Direct Plan Growth is rated High risk. Minimum SIP Investment is 500. Minimum Lumpsum Investment is 5000. Exit load of 0.50% if redeemed within 15 days.
1st Floor, Proms Complex, SBI
Colony, 1A Koramangala, 560034